Phanes Therapeutics presented phase 2 data at ASCO‑GI showing spevatamig (PT886), an anti‑CLDN18.2/CD47 bispecific antibody, produced encouraging responses when added to chemotherapy in first‑line CLDN18.2‑positive metastatic pancreatic ductal adenocarcinoma (PDAC). The company highlighted response rates and safety readouts that support further development in this hard‑to‑treat indication, where new immunotherapy combinations are in high demand.